Project Grant HT94252510839
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$750K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
This federal Project Grant award of $564,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by The Institute For Cancer Research (ICR) to explore the role of the MUL1 gene in prostate cancer development. The award period runs from May 1, 2025 to April 30, 2027. ICR, a non-profit research organization, will perform this advanced biomedical research to help transform healthcare for military service...
The Department of the Army Medical Command awarded a $699,534 project grant to the Institute of Cancer Research: Royal Cancer Hospital under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research on B7-H3 (CD276) as a therapeutic target in lethal prostate cancers. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation focused on "Targeting MNK/GRP78 Pathway to Disrupt Proteostasis Rewiring in Castration-Resistant Prostate Cancer". The $1,602,137 award, spanning from April 2025 to April 2028, aims to investigate innovative medical solutions for military personnel and the broader...
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...
The U.S. Defense Health Agency awarded King's College London a $1,712,517 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to identify molecular predictors of risk and validate the evolution of ductal carcinoma in situ (DCIS) over a 4-year period ending on September 29, 2027. As the prime awardee, King's College London will leverage its expertise in biomedical research to advance the scientific understanding of breast cancer progression. This award supports...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...